venBio Partners LLC Long-Term Concentrated

CIK: 0001776382 · Show all filings

Period: Q2 2019 (← Previous) (Next →)

Filing Date: May 20, 2020

Total Value ($000): $225,356 (100.0% shares, 0.0% debt)

Holdings (6)

— AKERO THERAPEUTICS INC 33.6%

Value ($000) $75,736 Shares 3,954,858 Est. Cost $19.15 Unrealized —

— PRECISION BIOSCIENCES INC 25.1%

Value ($000) $56,513 Shares 4,265,141 Est. Cost $17.95 Unrealized —

— TURNING POINT THERAPEUTICS I 24.2%

Value ($000) $54,549 Shares 1,340,265 Est. Cost $40.70 Unrealized —

APLS APELLIS PHARMACEUTICALS INC 11.2%

Value ($000) $25,340 Shares 1,000,000 Est. Cost $15.34 Unrealized +32.6%

— MENLO THERAPEUTICS INC 3.9%

Value ($000) $8,755 Shares 1,461,552 Est. Cost $4.12 Unrealized —

— VERONA PHARMA PLC 2.0%

Value ($000) $4,463 Shares 875,000 Est. Cost $9.65 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	AKERO THERAPEUTICS INC	3,954,858	$75,736	33.6%	$19.15	—	COM	00973Y108
—	PRECISION BIOSCIENCES INC	4,265,141	$56,513	25.1%	$17.95	—	COM	74019P108
—	TURNING POINT THERAPEUTICS I	1,340,265	$54,549	24.2%	$40.70	—	COM	90041T108
APLS	APELLIS PHARMACEUTICALS INC	1,000,000	$25,340	11.2%	$15.34	+32.6%	COM	03753U106
—	MENLO THERAPEUTICS INC	1,461,552	$8,755	3.9%	$4.12	—	COM	586858102
—	VERONA PHARMA PLC	875,000	$4,463	2.0%	$9.65	—	SPONSORED ADS	925050106